The light switch that wakes up dormant cancer cells

Introduction: when science relearns how to wake the enemy to beat it for good

Researchers at ETH Zurich have built a light-activated molecular switch capable of selectively destroying the receptors that let certain cancer cells dodge treatment by slipping into a dormant state. The discovery, published in Proceedings of the National Academy of Sciences and reported on July 5, 2026 by ScienceDaily, specifically targets cells that survive thanks to stress hormones, a subtle biological escape hatch that has long frustrated efforts to permanently clear tumors from the body.

This mechanism could one day help prevent relapses after cancer treatment, a problem that has haunted oncology for decades: cells that appear to have been eliminated can resurface years later, causing a devastating recurrence for patients and their families. The announcement fits into a broader acceleration of research against treatment resistance, one of the biggest challenges facing Western medicine today, and one that touches virtually every family that has ever sat in an oncology waiting room hoping the worst news was already behind them.

How cancer cells play hide-and-seek with medicine

Dormancy, a formidable survival strategy

Certain cancer cells dodge treatment by entering a dormant state triggered by stress hormones. In this standby state, they stop dividing actively, which makes them largely invisible to therapies designed to target rapidly proliferating cells, like conventional chemotherapy. This capacity for biological hibernation largely explains why certain cancers reappear years, even decades, after an apparent remission, triggering often unexpected relapses in patients otherwise considered cured.

The glucocorticoid receptor, conductor of this dormancy

The glucocorticoid receptor, a major mediator of stress hormone signaling, has emerged as a central regulator of dormancy in solid tumors, particularly in lung cancer. But inhibiting or degrading it systemically through conventional methods carries a risk of widespread toxicity, since this receptor also plays an essential role in inflammation and immunity throughout the body — two vital functions medicine cannot afford to disrupt carelessly.

The ingenuity of the molecular photo-switch

Three components for surgical precision

The researchers designed a molecular switch made of three parts: one element that attaches to the glucocorticoid receptor, another that attaches to the enzyme responsible for tagging the protein for destruction, and a flexible linker between the two. This type of molecule belongs to the PROTAC family — proteolysis-targeting chimeras — which degrade proteins with high specificity and have already proven effective in other areas of Western pharmaceutical research.

Light as a biological remote control

Under normal lighting conditions, the linker stays extended, positioning the enzyme close enough to tag the receptor for destruction. Exposed to a specific wavelength of light, the linker folds up, preventing proper alignment between the enzyme and the receptor, which halts the tagging process. This switch, according to lead co-author Robin Scheuplein, relies on existing medical technology, offering a realistic path toward localized treatments in the medium term.

Promising results in the lab

A confirmed wake-up call for dormant cells

In lung cancer cell cultures, the team observed the expected biological response: the treatment rapidly degraded the glucocorticoid receptors inside the tumor cells. Analyses of gene activity also indicated the cells were exiting their dormant state, an encouraging sign that the mechanism works as intended by the Swiss research team.

Remarkable photochemical performance

Tests showed that two of the linkers developed behaved exactly as expected, with near-quantitative photo-isomerization, no observed photodegradation, and thermal half-lives of three to twelve days in the solvent used. The compounds named KH-5-306 and KH-5-309 triggered powerful, specific and reversible degradation of the receptor, at low nanomolar concentrations, a result the study's authors consider solid.

Toward clinical applications still a ways off

The goal of a direct injection into the tumor

The researchers' long-term goal is to use this technology for precision treatments against cancer. They envision injecting the switch directly into a tumor, then using light to deactivate any molecule that migrates into surrounding healthy tissue, confining activity strictly to the tumor core and considerably reducing the side effects typically associated with conventional systemic treatments.

A very real physical limit: the reach of light

A significant current constraint is that light can only penetrate a few millimeters into tissue. For accessible tumors like some lung cancers, an endoscope can deliver light effectively. For deeper tumors, the team hopes to develop versions that respond to longer wavelengths, such as near-infrared, capable of penetrating deeper into tissue without harming surrounding healthy cells.

A potential that extends beyond lung cancer alone

A modular, adaptable platform

According to Robin Scheuplein, the team built a modular system that could also be used to deactivate other receptors. The concept could potentially extend to the estrogen receptors involved in certain hormone-driven breast cancers, or the androgen receptors linked to advanced prostate cancers — two areas where treatment resistance remains a major hurdle for oncologists.

The next steps in the research

Having demonstrated rapid receptor degradation and a reversal of dormancy in lung cancer cell cultures, the researchers now plan to test their photo-PROTACs in more complex systems, such as organoid models, an essential intermediate step before considering trials in living organisms and, eventually, human clinical trials.

What this discovery reveals about the future of oncology

A new family of tools against treatment resistance

This approach fits into a broader movement in oncology research, seeking to understand why certain cancer cells resist treatment by going dormant, then developing tools able to force them out of hiding and make them vulnerable again. Other research teams, notably at MIT, have recently studied how inflammation itself can wake dormant cells, sometimes in an unwanted and dangerous way for the patient, underscoring how complex this field remains.

The contrast with natural wake-up mechanisms

Unlike a wake-up triggered by inflammation, often uncontrolled and potentially harmful, this light-activated switch offers precise spatial and temporal control, a major advantage for limiting side effects while maximizing the therapeutic efficacy sought by the Swiss researchers and their international collaborators, who continue refining the chemistry behind each linker to squeeze out every possible margin of safety.

The broader context of Western cancer research

A scientific effort that benefits medicine worldwide

This Swiss breakthrough adds to a long list of discoveries from Western laboratories, whether European, North American or British, that continue to dominate fundamental research in cancer biology. That position of scientific strength is no accident: it rests on decades of public and private investment in institutions like ETH Zurich, regularly ranked among the world's top scientific universities.

An increasingly contested global scientific race

China too is investing massively in biomedical research, pushing Western institutions to accelerate their own efforts so as not to lose their historical lead in this strategic field. Maintaining Western scientific leadership in oncology will depend heavily on the ability to sustainably fund teams like Robin Scheuplein's and his colleagues', across funding cycles that often stretch far longer than any single political mandate.

Conclusion: measured hope for tomorrow's patients

What this breakthrough changes right now, and what it doesn't yet

This ETH Zurich discovery will not transform cancer treatment tomorrow. It does, however, represent a solid proof of concept, published in a rigorous scientific journal, that opens a credible path toward more precise therapies that are potentially less toxic to patients' healthy tissue.

What comes next depends on patience and scientific rigor

Patients and loved ones following this news with hope should understand that the road from a lab discovery to a treatment available in the clinic remains long, strewn with regulatory and scientific obstacles. But every step forward, like this one, brings Western medicine a little closer to solutions capable of reducing the relapses that strike so many families around the world.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my limits

I am neither a doctor nor a researcher in molecular biology. My role is to make a scientific discovery published in a peer-reviewed journal accessible, relying on accounts from reliable sources, without ever turning a proof of concept into a therapeutic promise for my readers.

My method and my acknowledged biases

I have an acknowledged bias toward cautious science communication: I'd rather under-promise than over-promise, especially on a subject as sensitive as cancer. I don't know whether this technology will ever lead to an approved treatment, and I refuse to speculate beyond what the researchers themselves state in their scientific publications.

Sources

Primary sources

ScienceDaily — A light switch wakes up dormant cancer cells, July 5, 2026

PubMed — Light-controlled disruption of cancer cell dormancy via photoswitchable stress hormone receptor degraders

Secondary sources

Optics and Photonics News — Light Switch Wakes Up Sleeping Cancer Cells, June 2026

Bionity — Light switch makes cancer vulnerable to attack, ETH Zurich

MIT News — Inflammation jolts sleeping cancer cells awake, September 18, 2025

Nature — Cancer research topic section